Skip to main content

Foundation for Sarcoidosis Research Awards Dr. Christen Vagts, University of Illinois Hospital and Clinic, Fellowship Grant for 2023–2025

CHICAGO, July 25, 2023 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) is pleased to announce that the FSR Sarcoidosis Research Fellowship for 2023-2025 is being awarded to Dr. Christen Vagts from FSR Global Sarcoidosis Clinic Alliance Founding Member, University of Illinois Hospital and Clinic, for her outstanding proposal, Immune Mediators of Active Advanced Pulmonary Sarcoidosis.

FSR has awarded over $1.2 million through the FSR Sarcoidosis Research Fellowship Grant program and is thrilled to award Dr. Vagts a fellowship in the amount of $150,000 over two-years to continue FSR's investment in support of promising early career investigators. FSR's Sarcoidosis Research Fellowship program was initiated in 2018 and has helped to support the research of eight fellows to build the pipeline for the next generation of sarcoidosis researchers. The FSR Fellowship Grant provides an opportunity for early-stage investigators to develop specialized skills and gain direct experience within the field of sarcoidosis.

“I am so honored to be the recipient of the FSR Fellowship grant,” said Dr. Vagts. “Improved understanding of how sarcoidosis-related inflammation drives pulmonary fibrosis is critical for new drug development and the creation of clinical strategies to help mitigate the risk of advance lung fibrosis.”

Dr. Vagts is an early career pulmonary and critical care physician scientist at the University of Illinois at Chicago (UIC) who has a passion for immunology as it pertains to sarcoidosis and other autoimmune diseases. Her research initiatives stem directly from clinical experiences managing patients with sarcoidosis at UIC’s Bernie Mac Sarcoidosis Translational Advanced Research (STAR) Center. As she embarked on her research career at the height of the COVID-19 pandemic, she evaluated the causes of sarcoidosis by focusing her attention on immunology. Advanced pulmonary sarcoidosis-related fibrosis (APSF) occurs in up to 30% of those with pulmonary sarcoidosis and carries significant morbidity and mortality. Dr. Vagt’s project will seek to identify potential genetic factors and inflammatory biomarkers that increase the risk of the potential development of advanced lung disease in sarcoidosis patients.

Dr. Vagts plans to apply gene sequencing techniques and a strategy that uses advanced software to understand and analyze complex data sets, called bioinformatics, to explore how changes in the immunological systems and cells may lead to sarcoidosis-related pulmonary fibrosis.

“It is with great enthusiasm that FSR grants Dr. Vagts the esteemed 2023-2025 FSR Sarcoidosis Research Fellowship. We are sure that her innovative research will yield significant findings and create fresh opportunities for the diagnosis, prevention, and the advancement of better patient outcomes for those impacted by sarcoidosis,” declared Mary McGowan, FSR's Chief Executive Officer.

To learn more about FSR's Fellowship and research programs, please visit:

About Sarcoidosis
Sarcoidosis is a rare inflammatory disease characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organs of the body. Despite increasing advances in research, sarcoidosis remains difficult to diagnose with limited treatment options and no known cure. Approximately 175,000 people live with sarcoidosis in the United States.

About the Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and to improving care for sarcoidosis patients through research, education, and support. Since its establishment in 2000, FSR has fostered over $6 million in sarcoidosis-specific research efforts. For more information about FSR and to join our community, visit:

Cathi Davis

A photo accompanying this announcement is available at:

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.